



# The ripple effect 2.0: from global health to domestic value

**Suggested social media posts to promote the report and the data**

Impact Global Health

## Report

- [impactglobalhealth.org/insights/report-library/ripple-effect-2](https://impactglobalhealth.org/insights/report-library/ripple-effect-2)
- Short link: [tinyurl.com/ripple-effect-2](https://tinyurl.com/ripple-effect-2)

### Case study 1: From TB prevention to cancer: the BCG vaccine treating bladder cancer

- [impactglobalhealth.org/insights/report-library/bcg-vaccine](https://impactglobalhealth.org/insights/report-library/bcg-vaccine)
- Short link: [tinyurl.com/bcg-vaccine](https://tinyurl.com/bcg-vaccine)

### Case study 2: From targeted solution to global maternal health asset: the JADA System

- [impactglobalhealth.org/insights/report-library/jada-system](https://impactglobalhealth.org/insights/report-library/jada-system)
- Short link: [tinyurl.com/jada-system](https://tinyurl.com/jada-system)

### Case study 3: From malaria research to protecting aging populations: AS01 Adjuvant in Shingrix

- [impactglobalhealth.org/insights/report-library/shingrix-vaccine](https://impactglobalhealth.org/insights/report-library/shingrix-vaccine)
- Short link: [tinyurl.com/AS01-shingrix-vaccine](https://tinyurl.com/AS01-shingrix-vaccine)

1. Think global health R&D only benefits patients in LMICs? Think again.

Our latest report, The Ripple Effect 2.0, shows global health R&D is a strategic investment strengthening innovation pipelines, boosting domestic economies, and improving health outcomes in donor countries.

Read the report: [tinyurl.com/ripple-effect-2](http://tinyurl.com/ripple-effect-2)

2. From malaria to shingles. From TB to cancer.

Global health R&D and resulting innovations for these diseases led to new treatments for high-income countries:

Malaria research → Shingrix shingles vaccine

TB vaccine → bladder cancer treatment

Global health R&D delivers products that save lives and cross disease areas. Read the case studies: [tinyurl.com/bcg-vaccine](http://tinyurl.com/bcg-vaccine) & [tinyurl.com/AS01-shingrix-vaccine](http://tinyurl.com/AS01-shingrix-vaccine)

3. BCG was developed to fight TB. Today, it saves lives from bladder cancer.

Malaria research developed the AS01 adjuvant which is now used in GSK's shingles vaccine, Shingrix.

The JADA System was developed for postpartum haemorrhages in LMICs and is now used in the US

Global health R&D is not just about helping others, it's about shared prosperity, security, and resilience.

Read The Ripple Effect 2.0 to learn more: [tinyurl.com/ripple-effect-2](http://tinyurl.com/ripple-effect-2)

4. Solutions designed for the most resource-constrained settings can deliver gains everywhere.

In the US, use of the JADA System (a global health innovation for postpartum haemorrhage), is projected to:

- Control 597,000 severe cases
- Save 1,000 lives
- Generate \$4.5bn in health-system savings

Read more: [tinyurl.com/jada-system](http://tinyurl.com/jada-system)

5. Impact Global Health's [tag] newest report, The Ripple Effect 2.0, provides quantitative, country-specific evidence showing how selected global health innovations improve health outcomes and deliver economic value across the US, UK, Japan and Europe.

Read the report: [tinyurl.com/ripple-effect-2](http://tinyurl.com/ripple-effect-2)

6. Global health R&D = dual benefits for LMICs + HICs

Some global health innovations go on to become the founding blocks for health innovations used in high-income countries.

The Ripple Effect 2.0 shows why long-term, consistent R&D funding matters

Read the report: [tinyurl.com/ripple-effect-2](http://tinyurl.com/ripple-effect-2)